[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-arterial-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-arterial-disease":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,109,0,25,[9,52,76,101,127,154,178,202,237,269,296,320,364,388,421,449,470,493,517,538,557,579,601,622,646],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100604025","evero-drug-coated-balloon-dcb-randomized-trial-100604025",false,"NCT07144150","EVERO Drug-coated Balloon (DCB) Randomized Trial","Advance Evero™ 18 Everolimus-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter Versus Paclitaxel-coated Ballons in Patients With Femoropopliteal Disease (EVERO Trial)","Inclusion Criteria:\n\n1. Documented PAD with Rutherford classification 2 - 4; and\n2. De novo or restenotic (non-stented) target lesion located in the native superficial femoral artery (SFA), popliteal artery (P1 or P2), or both native SFA and popliteal arteries.\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria\n\n1. Less than 18 years old;\n2. Inability or refusal to give informed consent by the patient or legally authorized representative;\n3. Life expectancy ≤ 12 months, per investigator assessment;\n4. Pregnant (or if absence of pregnancy is not verified by negative pregnancy test within 7 days of planned procedure), lactating, planning to become pregnant within 12 months of the planned procedure, or unwilling to use contraception for 12 months following the planned procedure;\n5. Unable or unwilling to comply with the follow-up schedule; or\n6. Simultaneously participating in another investigational drug or device study unless the patient is at least 30 days beyond the primary endpoint of any previous study.","ALL","18 Years",{"count":20,"type":21},410,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \\[DCB\\]) in the treatment of the femoropopliteal artery lesions in patients with peripheral arterial disease (PAD). Specifically, the Randomized-Controlled Trial (RCT) is designed to demonstrate non-inferior safety and non-inferior effectiveness of the Evero DCB when compared to commercially available paclitaxel DCBs (pDCBs).",[27,28],"Peripheral Vascular Disease","Peripheral Arterial Disease",[30,31,32,33,34,35,36,37,38],"Intermittent claudication","Paclitaxel","Everolimus","Rapamycin","Drug-coated balloon (DCB)","Percutaneous transluminal angioplasty (PTA)","Femoropopliteal artery","Superficial femoral artery (SFA)","Popliteal artery","RECRUITING","2026-07-01",{"date":42,"type":43},"2026-07-02","ACTUAL",{"date":45,"type":43},"2026-04-17",{"date":47,"type":21},"2032-10",{"name":49,"class":50},"Cook Research Incorporated","INDUSTRY",5,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100557901","use-of-thermal-imaging-camera-to-assess-perfusion-before-and-after-vascular-intervention-100557901","NCT06544135","Use of Thermal Imaging Camera to Assess Perfusion Before and After Vascular Intervention","TIC","Inclusion Criteria:\n\n* Lower extremity peripheral artery disease with tissue loss consistent with Rutherford classification V or VI.\n* Planned lower extremity endovascular intervention\n\nExclusion Criteria:\n\n* Non-arterial ulcers\n* Pregnant","99 Years",{"count":7,"type":21},"1 Year","OBSERVATIONAL","This is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure.\n\nThe main question this study aims to answer is:\n\n\\- Are temperature measurements from a forward looking infrared (FLIR) camera of the lower extremity useful in predicting outcome of revascularization procedures?",[28,65,66],"Critical Limb Ischemia","Critical Lower Limb Ischemia",{"date":42,"type":43},{"date":69,"type":43},"2025-04-14",{"date":71,"type":21},"2027-10",{"name":73,"class":74},"University Hospitals Cleveland Medical Center","OTHER",3,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100423929","adapted-physical-activity-in-patients-with-lower-limb-peripheral-arterial-disease-100423929","NCT04800276","Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease","Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease (ACTIV'AO)","ACTIV'AO","Inclusion Criteria:\n\n* Patient with Lower Limb Peripheral Arterial Disease with IPSC \\\u003C 0.90, arterial stenosis in the lower limbs and intermittent claudication\n* No contraindication to physical activity\n* Socially insured patients over 18 ;\n* Patient who has signed the consent form.\n\nExclusion Criteria:\n\n* Severe or unstable cardiopulmonary pathologies, contraindicating exercise training\n* Unstable angina or myocardial infarction \\\u003C3 months\n* Severe rheumatological pathology of the lower limbs\n* Amputee of a lower or upper limb fitted with a device\n* Extensive dermatosis of the lower limbs\n* Known NYHA grade III or IV heart failure\n* Known severe respiratory pathology\n* Parkinson's disease, hemiplegia or paraplegia\n* Adults subject to enhanced protection, deprived of their liberty by judicial or administrative decision\n* Persons unable to consent\n* Be in a period of exclusion from other interventional research.\n* Any event (injury, surgery, etc.) occurring during the protocol period that could have an impact on results.",{"count":85,"type":21},70,[24],"The prevalence of peripheral arterial disease is 12.2% in France. Intermittent claudication is the most common symtom of this disease. During physical exercise, such as walking, blood oxygen (O2) requirements increase. The development of atherosclerosis in the lower limbs, causes narrowing of the arteries and limits the increase in blood flow required for muscular effort. Patients then experience muscle pain, the intensity of which gradually increases until it forces them to stop. After stopping, the pain subsides and disappears in less than 10 minutes.\n\nThe location of the pain (calves and\u002For thighs and\u002For buttocks) is related to the location of the ischemia (distal in the calf, proximal in the thigh or buttock, or proximo-distal if several locations). This can have different consequences on the biomechanical parameters of walking and muscle activity. To date, the impact of this localization on physical capacity has never been studied.\n\nThese limitations are very disabling and impact the quality of life of patients.\n\nIn addition, poor lower limb performance is associated with higher mortality. Reducing symptomatology and improving functional abilities is therefore a major issue in patients with peripheral arterial disease. This can be achieved through the practice of an Adapted Physical Activity, an essential recommendation in the care of patients with peripheral arterial disease.\n\nOur main hypothesis is that the physical activity rehabilitation protocol \"Activ'AO\" will improve the functional capacities of patients with peripheral arterial disease who have followed the program with the localization of ischemia with a greater consideration than in patients in the group following a \"standard\" APA protocol. Improvements in functional abilities (such as walking) will lead to improvements in quality of life.",[28],[28,90,91],"Adapted Physical Activity","maximum walking distance","2026-06-30",{"date":40,"type":43},{"date":95,"type":43},"2021-02-11",{"date":97,"type":21},"2026-11-11",{"name":99,"class":74},"Centre Hospitalier le Mans",1,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":100},"100644498","predictors-of-major-adverse-limb-events-after-endovascular-iliac-stenting-a-real-world-cohort-study-100644498","NCT07672249","Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study","Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study (PREMISE-ILIAC Study)","PREMISE-ILIAC","Inclusion Criteria:\n\nAdult patients aged ≥18 years, of both male and female sex\n\n* Presence of haemodynamically significant stenosis or occlusion of the common iliac artery (CIA) and\u002For external iliac artery (EIA), documented by computed tomography angiography, magnetic resonance angiography, or diagnostic angiography\n* Symptomatic peripheral artery disease, including lifestyle-limiting intermittent claudication (Rutherford category 2-3) or chronic limb- threatening ischaemia (CLTI; Rutherford category 4-6), refractory to optimal medical therapy\n* Treatment with endovascular iliac artery stenting (covered or uncovered; balloon-expandable or self-expanding devices) as the primary revascularisation strategy\n* De novo iliac lesions only\n* Availability of complet\n\nExclusion Criteria:\n\nPrimary open surgical revascularisation of the iliac axis (e.g., aorto- bifemoral bypass or endarterectomy).\n\n* Previous stenting of the target iliac segment (in-stent restenosis cases excluded).\n* Aorto-iliac aneurysmal disease as the primary indication for treatment (including EVAR or fenestrated endografts).\n* Hybrid procedures with concomitant infrainguinal bypass surgery.\n* Incomplete clinical, procedural, or follow-up data preventing assessment of study endpoints.\n* Loss to follow-up without documented clinical outcomes.",{"count":110,"type":21},98,"Peripheral arterial disease involving the iliac arteries is a common manifestation of systemic atherosclerosis and a major cause of lifestyle-limiting claudication and chronic limb-threatening ischemia. Endovascular iliac artery stenting has become the preferred treatment strategy for most iliac lesions, including complex TransAtlantic Inter-Society Consensus II (TASC II) C and D lesions, owing to high technical success rates and lower perioperative morbidity compared with open surgical reconstruction.\n\nDespite widespread adoption of endovascular treatment, available evidence regarding predictors of major adverse limb events (MALE) after iliac artery stenting remains limited, particularly in unselected real-world populations with substantial comorbidity burden. Patient-related factors, including frailty, may contribute to post-procedural outcomes in addition to lesion-related characteristics.\n\nThis retrospective single-center cohort study will evaluate clinical outcomes following endovascular iliac artery stenting in consecutive adult patients treated at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study will assess the occurrence of major adverse limb events (MALE), primary patency, peri-procedural complications, target lesion revascularization, restenosis or occlusion, and all-cause mortality. Clinical, anatomical, and procedural factors associated with adverse limb outcomes, including frailty assessed by the modified five-item Frailty Index (mFI-5), will also be investigated.",[28,113,114,115],"Aortoiliac Occlusive Disease","Chronic Limb-Threatening Ischemia","Intermittent Claudication",[28,117,118],"Iliac Artery Stenting","Endovascular Revascularization","2026-06-26",{"date":92,"type":43},{"date":122,"type":43},"2026-06-16",{"date":124,"type":21},"2026-07-16",{"name":126,"class":74},"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":100},"100640367","phase-1-the-pharmacokinetics-and-pharmacodynamics-study-of-evategrel-cg-0255-besylateand-plavix-in-healthy-participants-100640367","NCT07619885","The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants","A Pivotal Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of CG-0255 Besylate and Plavix® in Healthy Participants","Inclusion Criteria:\n\n* Participants must be fully informed about the study, willing to participate, and sign the informed consent document prior to any procedure.\n* Healthy male and female participants, aged 18 to 55 years (inclusive) at time of signing informed consent form.\n* Body mass index (BMI) between 18 and 32 kg\u002Fm2 (inclusive) at screening and body weight between 45 and 120 kg (inclusive).\n* Smoking \\\u003C 10 cigarettes (10-20 mg of nicotine\u002Fmonth) or equivalent amount of nicotine products per month within 6 months prior to screening and agree to abstain from tobacco and\u002For nicotine products during the study.\n* Generally normal health, or abnormalities deemed non-clinically significant by the Investigator or designee based on medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory tests at the screening and at the admission.\n* For female participants,\n\n  1. Woman of child-bearing potential (WOCBP) must be non-pregnant and non-lactating, and must agree to use highly effective contraceptive methods and abstain from egg collection or donation from the screening period to 3 months after the last dose of the study treatment (CG-0255 Besylate or Plavix®). The male partner of a female participant also needs to use condoms during this period.\n  2. Woman of non-childbearing potential (WONCBP) must be post menopausal (spontaneous amenorrhea for at least 12 consecutive months prior to dosing) with confirmation by documented FSH levels ≥40 mIU\u002FmL; or surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or bilateral tubal ligation) at least 3 months prior to dosing.\n* Male participants considered fertile must agree to not plan to father a child, not donate sperm and take effective contraceptive methods from the screening period to 3 months after the last dose of the study treatment. The female partner of a male participant also needs to use a highly effective contraceptive method during this period.\n* Male participants (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the screening period to 3 months after the last dose of the study treatment.\n* Participants must be able to communicate well with the Investigator or designee, as well as understand and adhere to the study's requirements.\n\nExclusion Criteria:\n\n* Difficulty with venous blood collection or a history of fainting upon seeing blood or needles.\n* Clinically relevant drug intolerance or allergy or known or suspected hypersensitivity to any component of CG-0255 Besylate or Plavix®, or other related drugs.\n* Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days (or 5 times half-life, whichever is longer) prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days (or 5 times half-life, whichever is longer) prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.\n* Current or unresolved digestive tract diseases (dyspepsia, gastroesophageal reflux, gastro-hemorrhage, or digestive tract ulcer disease) within the past 6 months, or frequent (\\> 1 time\u002Fweek) digestive tract symptoms including dysphagia, abdominal pain, abdominal distension, acid regurgitation, belching, hematemesis, bloody stool, anorexia, nausea, heartburn, and other symptoms that may increase the risk of bleeding, as determined by the Investigator or designee.\n* Any clinically significant diseases including but not limited to pulmonary, cardiovascular, gastrointestinal, hematological, endocrinological, immunological, dermatological, malignant diseases, mental and nervous systems, and other related diseases or any other condition at the discretion of the Investigator or designee.\n* History of previous or current active bleeding (such as intracranial hemorrhage, gastrointestinal hemorrhage, urethral hemorrhage, hemoptysis, vitreous hemorrhage, bleeding caused by stool and hemorrhoids), transient ischemic attack or stroke, abnormal bleeding (such as prolonged bleeding time after tooth extraction), presence of petechiae and\u002For ecchymosis on physical examination, or suspected vascular malformations (such as aneurysms or early-onset stroke, not exceeding the age limit specified in the inclusion criteria).\n* Hemoglobin \\\u003C120 g\u002FL for males and \\\u003C110 g\u002FL for females at screening.\n* Medication history of NSAIDs (including Aspirin) or other drugs that may affect coagulation function (e.g, oral anticoagulants) within 4 weeks before the screening.\n* Platelet count \\\u003C 120 × 10\\^9\u002FL at screening.\n* Laboratory measures with values above the 1.5 × upper limits of normal (ULN) and deemed clinically significant by the Investigator or designee for the alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST).\n* Clinically significant ECG abnormalities (QTcF interval ≥ 450 ms for male, ≥ 470 ms for female (Fridericia's Correction)) or vital signs abnormalities (systolic BP lower than 90 or over 140 mmHg, diastolic BP lower than 50 or over 90mmHg, HR less than 50 or over 100 bpm, or RR less than 10 or over 22 bpm) at screening.\n* Major surgery within 3 months prior to the first dose of study treatment or plans for surgery during the study.\n* Use of prescription, nonprescription or dietary supplements (e.g. food supplements and herbal supplements) within 14 days or 5 times the half life (whichever is longer) prior to the first dose of study treatment (excluding drug products without significant systemic absorption at the discretion of the Investigator or designee), or depot injection or implant within 3 months prior to first dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily).\n* Vaccinated within 14 days prior to the first dose of study treatment or planned to be vaccinated during the study.\n* Consuming quinine containing products, including quinine water, tonic water bitter lemon, jello shots, any quinine preparations or Cinchona tree bark reparations (e.g., herbal medications containing Cinchona tree bark), and grapefruit or products containing grapefruit, or participants have engaged strenuous exercise or any other factors affecting drug absorption, distribution, metabolism and excretion within 7 days before the first dose of study treatment.\n* History of drug abuse within 1 year before screening, or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine \\[PCP\\], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.\n* Positive urine drug screen, urine cotinine test, or alcohol breath test at screening or at the admission.\n* Positive pregnancy test or lactating female participant at screening or at the admission.\n* Donation of plasma within 7 days prior to the first dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to the first dosing.\n* History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).\n* Known hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.\n* Excessive drinking of tea, coffee, or caffeine-containing beverage (\\>600 mg\u002Fday) within 30 days before screening; intake of caffeine- or xanthine rich foods or drinks (e.g., coffee, tea, chocolate, cola drinks) within 48 hours prior to the first dose of study treatment, which may metabolize into caffeine or xanthine.\n* Positive screening for human immunodeficiency virus (HIV) antigen and antibody, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV) antibody at screening.\n* Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin as calculated per CKD-EPI equation, at screening.\n* Use of any drugs known to induce or inhibit hepatic drug metabolism (including CYP2C19 inducers or inhibitors) within 30 days prior to the first study drug administration or 5 half-lives (whichever is longer) until the end of the study.\n* Participants deemed ineligible to participate in this study by the Investigator or designee.",true,"55 Years",{"count":137,"type":21},136,[139],"PHASE1","CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes. This is a randomized, open-label and Plavix®-controlled study to compare the PK and PD of CG-0255 Besylate and Plavix® in healthy participants.",[142,143,144,28],"Acute Coronary Syndromes (ACS)","Recent Myocardial Infarction","Recent Stroke","2026-06-24",{"date":147,"type":43},"2026-06-29",{"date":149,"type":21},"2026-06",{"date":151,"type":21},"2026-12",{"name":153,"class":50},"Shanghai CureGene Pharmaceutical Co., Ltd.",{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100610131","phase-3-efficacy-and-safety-of-orforglipron-in-participants-with-peripheral-artery-disease-100610131","NCT07223593","Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease","A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial","ATTAIN-PAD","Inclusion Criteria:\n\n* Have symptomatic PAD with intermittent claudication of Fontaine Stage II\n* Have an Ankle Brachial Index (ABI) of 0.9 or less\n\nExclusion Criteria:\n\n* Have a body mass index (BMI) less than 23 kilogram per square meter (kg\u002Fm2)\n* Have Hemoglobin A1c (HbA1c) greater than 10%\n* Have walking ability limited by conditions other than PAD\n* Have a planned lower limb surgery or any other surgery affecting walking ability\n* Had peripheral revascularization procedure within 90 days prior to the day of screening or planning to undergo peripheral revascularization during the clinical trial\n* Had stroke, transient ischemic attack, myocardial infarction, coronary or carotid revascularization, or hospitalization for unstable angina pectoris within 60 days prior to screening\n* Have heart failure presently classified as being in New York Heart Association class III - IV",{"count":163,"type":21},1205,[165],"PHASE3","The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.",[28],"2026-06-19",{"date":170,"type":43},"2026-06-23",{"date":172,"type":43},"2025-10-31",{"date":174,"type":21},"2028-06",{"name":176,"class":50},"Eli Lilly and Company",140,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":134,"sex":17,"minAge":185,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":100},"100540630","early-phase-1-impact-of-nrf2-activation-on-macrovascular-microvascular--leg-function--walking-capacity-in-peripheral-artery-disease-100540630","NCT06319339","Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease","Impact of Nrf2 Activation on Macrovascular Function, Microvascular Function, Leg Function, and Walking Capacity in Patients With Peripheral Artery Disease","Inclusion Criteria:\n\nPeripheral artery disease (PAD) participants:\n\n* Able to provide written informed consent\n* 50-75 years of age\n* Diagnosed as Fontaine stage II-III\n* History of exercise-induced claudication\n* Females must be postmenopausal (cessation of menses for \\> 24 months)\n* Normal renal function (serum creatinine-estimated glomerular filtration rate \\>= 60 mL\u002Fmin) or evidence of stable renal function within the last 6 months\n* Normal hepatic function (alanine transaminase \\\u003C 87.5 U\u002FL, alkaline phosphatase \\\u003C 260 U\u002FL, total bilirubin 1.8 mg\u002FdL) or evidence of stable hepatic function within the last 6 months\n* Complete blood count:\n\n  * Females: red blood cell 4-5 trillion cells\u002FL, hemoglobin 12-15 g\u002FdL, hematocrit 34-45%, white blood cell count 3-10 billion cells\u002FL, platelet count 160-380 billion\u002FL, and normal lymphocyte count \\> 700 million lymphocytes\u002FL, or evidence of stable blood counts within the last 6 months\n  * Males: red blood cell 4-6 trillion cells\u002FL, hemoglobin 13-17 g\u002FdL, hematocrit 38-49%, white blood cell count 3-10 billion cells\u002FL, platelet count 135-320 billion\u002FL, and normal lymphocyte count \\> 700 million lymphocytes\u002FL, or evidence of stable blood counts within the last 6 months\n\nAge-matched control participants:\n\n* Able to provide written informed consent\n* 50-75 years of age\n* No evidence of peripheral occlusive disease (ankle-brachial index \\> 0.90)\n* Females must be postmenopausal (cessation of menses for \\> 24 months)\n* Normal renal function (serum creatinine-estimated glomerular filtration rate \\>= 60 mL\u002Fmin), or evidence of stable renal function within the last 6 months\n* Normal hepatic function (alanine transaminase \\\u003C 87.5 U\u002FL, alkaline phosphatase \\\u003C 260 U\u002FL, total bilirubin 1.8 mg\u002FdL ), or evidence of stable hepatic function within the last 6 months\n* Complete blood count:\n\n  * Females: red blood cell 4-5 trillion cells\u002FL, hemoglobin 12-15 g\u002FdL, hematocrit 34-45%, white blood cell count 3-10 billion cells\u002FL, platelet count 160-380 billion\u002FL, and normal lymphocyte count \\> 700 million lymphocytes\u002FL\n  * Males: red blood cell 4-6 trillion cells\u002FL, hemoglobin 13-17 g\u002FdL, hematocrit 38-49%, white blood cell count 3-10 billion cells\u002FL, platelet count 135-320 billion\u002FL, and normal lymphocyte count \\> 700 million lymphocytes\u002FL, or evidence of stable blood counts within the last 6 months\n\nExclusion Criteria:\n\nPeripheral artery disease (PAD) participants:\n\n* • Pain at rest and\u002For tissue loss due to PAD (Fontaine stage IV PAD)\n* Acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma\n* Limited walking capacity from conditions other than PAD\n* No physical exam to assess exercise limitations in the past year\n* Currently pregnant or nursing\n* Blood work and medical history NOT demonstrating:\n\n  * Normal renal function (serum creatinine-estimated glomerular filtration rate \\>\\> 60 mL\u002Fmin)\n  * Normal hepatic function (alanine transaminase 0-35 IU\u002FL, alkaline phosphatase 30-120 IU\u002FL, total bilirubin 2-17 micromoles\u002FL),\n* Diagnosis of multiple sclerosis or psoriasis\n* Diagnosis of gastrointestinal disorders (e.g., moderate IBS, Crohn's disease, etc.\n* Concomitant use of dimethyl fumarate\n* Hypersensitivity to diroximel fumarate, dimethyl fumarate, or to any of the excipients of VUMERITY\n* Ulcers, gangrene, or necrosis of the foot (Fontaine stage IV PAD)\n* Complete blood count NOT within ranges:\n\n  * Females: red blood cell 4-5 trillion cells\u002FL, hemoglobin 12-15 g\u002FdL, hematocrit 34-45%, white blood cell count 3-10 billion cells\u002FL, platelet count 160-380 billion\u002FL, and normal lymphocyte count 1-4.8 billion lymphocytes\u002FL\n  * Males: red blood cell 4-6 trillion cells\u002FL, hemoglobin 13-17 g\u002FdL, hematocrit 38-49%, white blood cell count 3-10 billion cells\u002FL, platelet count 135-320 billion\u002FL, and normal lymphocyte count 1-4.8 billion lymphocytes\u002FL\n\nAge-matched control participants:\n\n* Positive diagnosis of PAD\n* No physical exam to assess exercise limitations in the past year\n* Any exercise limitations as determined at last physical exam\n* Limited walking capacity from musculoskeletal injury\n* Currently pregnant or nursing\n* Renal function not within normal ranges (serum creatinine-estimated glomerular filtration rate \\>\\> 60 mL\u002Fmin)\n* Hepatic function not within normal ranges (alanine transaminase 0-35 IU\u002FL, alkaline phosphatase 30-120 IU\u002FL, total bilirubin 2-17 micromoles\u002FL)\n* Complete blood count NOT within ranges:\n\n  * Females: red blood cell 4-5 trillion cells\u002FL, hemoglobin 12-15 g\u002FdL, hematocrit 34-45%, white blood cell count 3-10 billion cells\u002FL, platelet count 160-380 billion\u002FL, and normal lymphocyte count 1-4.8 billion lymphocytes\u002FL\n  * Males: red blood cell 4-6 trillion cells\u002FL, hemoglobin 13-17 g\u002FdL, hematocrit 38-49%, white blood cell count 3-10 billion cells\u002FL, platelet count 135-320 billion\u002FL, and normal lymphocyte count 1-4.8 billion lymphocytes\u002FL","50 Years","75 Years",{"count":188,"type":21},20,[190],"EARLY_PHASE1","Peripheral artery disease (PAD) is associated with elevated oxidative stress, and oxidative stress has been implicated as the cause of reduced endothelial reactivity in individuals with PAD. Endothelial function is important because the endothelium contributes to the dilation of arteries during exercise, thereby implicating impaired endothelial function as a mechanism contributing to exacerbated exercise-induced ischemia. Therefore, the purpose of this study is to test the hypothesis that acute exogenous diroximel fumarate (Vumerity) intake will improve antioxidant capacity, thereby reducing oxidative stress and improving vascular function and walking capacity in those with PAD. During this study, participants will be administered diroximel fumarate or a placebo, and the acute effects of diroximel fumarate on vascular function and walking capacity will be assessed. Vascular function and walking capacity will be assessed with flow-mediated dilation, arterial stiffness, head-up tilt test, blood biomarkers, near-infrared spectroscopy, and a treadmill test. There will be a follow-up visit to assess blood work after diroximel fumarate.",[193,194,28,195],"Peripheral Artery Disease","Peripheral Vascular Diseases","Peripheral Arterial Occlusive Disease",{"date":145,"type":43},{"date":198,"type":43},"2024-11-14",{"date":151,"type":21},{"name":201,"class":74},"University of Nebraska",{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":211,"studyType":62,"phases":4,"briefSummary":212,"conditions":213,"keywords":217,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":232,"leadSponsor":234,"locationsCount":100},"100644229","effectiveness-of-an-inpatient-rehabilitation-and-prosthetic-training-model-in-patients-with-vascular-and-metabolic-transfemoral-amputation-100644229","NCT07665775","Effectiveness of an Inpatient Rehabilitation and Prosthetic Training Model in Patients With Vascular and Metabolic Transfemoral Amputation","Effectiveness of an Inpatient Multidisciplinary Rehabilitation and Prosthetic Training Model in Patients With Vascular and Metabolic Transfemoral Amputation Treated at a National Rehabilitation Center: An Ambispective Cohort Study","Inclusion Criteria:\n\n* Unilateral transfemoral amputation secondary to vascular disease or diabetes-related complications.\n* Participation in the INRLGII inpatient prosthetic rehabilitation program.\n* Availability of complete clinical records or willingness to participate in follow-up assessments .\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Current prosthesis user before admission to the INRLGII rehabilitation program.\n* Bilateral major lower-limb amputation.\n* Inability to complete follow-up assessments.\n\nWithdrawal Criteria\n\n* Incomplete or inconsistent clinical information.\n* Loss to follow-up during the 6-month observation period.\n* Participant withdrawal of consent.",{"count":210,"type":21},54,"6 Months","Patients with vascular and metabolic transfemoral amputations experience substantial functional limitations and high rates of prosthetic abandonment. Although multidisciplinary inpatient rehabilitation programs have been associated with improved outcomes, evidence regarding their effectiveness in low- and middle-income countries remains limited.\n\nThis study aims to evaluate the effectiveness of an inpatient rehabilitation and prosthetic training model implemented at the National Institute of Rehabilitation \"Luis Guillermo Ibarra Ibarra\" (INRLGII), Mexico. An ambispective cohort design will be used, including a retrospective review of patients treated between 2013 and 2025 and a prospective cohort enrolled between 2026 and 2029.\n\nThe primary objective is to determine the proportion of patients who achieve functional prosthesis use after hospital discharge. Secondary objectives include identifying clinical, metabolic, functional, and psychosocial factors associated with successful prosthetic use, adherence, and abandonment.",[214,215,28,216],"Diabetes Mellitus","Transfemoral Amputation","Vascular Thrombosis",[215,218,214,219,220,221,222,223,224,225,226,227],"Vascular Amputation","Prosthetic Rehabilitation","Lower Limb Amputation","Prosthesis Use","Prosthetic Adherence","Prosthetic Abandonment","Functional Outcomes","Inpatient Rehabilitation","Multidisciplinary Care","Houghton Scale","NOT_YET_RECRUITING","2026-06-18",{"date":145,"type":43},{"date":168,"type":21},{"date":233,"type":21},"2030-09",{"name":235,"class":236},"Instituto Nacional de Rehabilitacion","OTHER_GOV",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":245,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":247,"conditions":248,"keywords":253,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":100},"100640402","radial-access-data-in-vascular-interventions-registry-100640402","NCT07614386","Radial Access Data in Vascular Interventions Registry","Radial Access Data in Vascular Interventions: A Prospective Observational Registry Study","RADIUS","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients undergoing routine percutaneous vascular interventions via radial or ulnar artery access\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Procedures performed without radial or ulnar artery access\n* Incomplete procedural or clinical data\n* Refusal to participate in the registry",{"count":246,"type":21},20000,"The RADIUS study is a prospective observational registry designed to collect real-world data regarding radial and ulnar artery access in percutaneous vascular interventions. The study aims to evaluate procedural characteristics, access-site complications, procedural success, and short-term clinical outcomes associated with transradial and transulnar vascular access.\n\nPatients undergoing routine percutaneous vascular interventions via radial or ulnar artery access at Mersin Medical Park Hospital will be consecutively enrolled. Demographic, clinical, angiographic, procedural, and post-procedural data will be prospectively collected and analyzed.\n\nThe study was initially designed as a single-center registry; however, following Institutional Review Board (IRB) approval, expansion into a multicenter registry with participating centers is planned.\n\nThis study is observational in nature and does not involve any experimental treatment, device, or intervention beyond standard clinical care.",[249,250,251,252,28],"Radial Artery Occlusion","Radial Artery Spasm","Vascular Access Complications","Coronary Artery Disease",[254,255,256,257,258,259,260,250,261],"Radial access","Ulnar access","Transradial intervention","Coronary angiography","Percutaneous coronary intervention","Vascular complications","Radial artery occlusion","Registry",{"date":170,"type":43},{"date":264,"type":43},"2026-05-15",{"date":266,"type":21},"2031-05-20",{"name":268,"class":74},"Mersin Medicalpark Hastanesi",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":284,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":292,"leadSponsor":294,"locationsCount":100},"100641226","phase-3-evaluating-bu-yang-huanwu-decoction-for-early-diabetic-vascular-disease-100641226","NCT07658807","Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease","Evidence-Based Evaluation and New Drug Translation Research of Early Intervention With the Classic Traditional Chinese Medicine Formula Bu Yang Huanwu Decoction for Preventing and Treating Diabetic Lower Extremity Vascular Disease","Inclusion Criteria:\n\n1. Aged 18 to 70 years (inclusive), male or female.\n2. Diagnosed with diabetes mellitus according to the Chinese Diabetes Society (2024) Guidelines.\n3. Glycated hemoglobin (HbA1c) \\\u003C 12%, with recent fasting blood glucose \\\u003C 7.0 mmol\u002FL OR postprandial blood glucose \\\u003C 10.0 mmol\u002FL, and triglycerides \\\u003C 1.7 mmol\u002FL.\n4. Diagnosed with LEAD, meeting the following criteria:\n\n   Rutherford Classification 2, 3, or 4.\n\n   Resting ABI ≤ 0.90, OR for patients with exertional symptoms and resting ABI \\> 0.90, a post-exercise treadmill test showing an ABI decrease of ≥15%.\n\n   Evidence of lower limb arterial stenosis or occlusion confirmed by duplex ultrasound, CTA, MRA, or DSA.\n5. TCM Pattern Diagnosis: Must conform to the TCM syndrome of Qi Deficiency and Blood Stasis, as defined by the study's TCM diagnostic criteria (referencing \"Practical Diagnostic Criteria for Blood Stasis Syndrome\" and \"Integrated Chinese and Western Medicine Peripheral Vascular Disease\"):\n\n   Main Symptom: Lower limb weakness, or feeling of heaviness\u002Fdiscomfort after prolonged walking.\n\n   Secondary Symptoms: Shortness of breath\u002Flassitude in speaking; dry mouth with desire to drink; scaly skin.\n\n   Tongue \\& Pulse: Tongue with teeth marks, pale-purple with petechiae\u002Fecchymosis; thin and choppy pulse.\n\n   (Diagnosis confirmed by meeting 1 main symptom OR 2 secondary symptoms, assessed by a qualified TCM practitioner.)\n6. Voluntarily signs the Informed Consent Form (ICF) and is willing and able to comply with all study procedures and visits.\n\nExclusion Criteria:\n\n1. Known bleeding disorders or history of intracranial hemorrhage.\n2. Current use of anticoagulants (e.g., warfarin, dabigatran, factor Xa inhibitors).\n3. Presence of active infection.\n4. Severe cardiac abnormalities on resting ECG (e.g., heart failure, ventricular tachycardia, ventricular fibrillation, multifocal ventricular contractions, prolonged corrected QT interval).\n5. History of acute coronary syndrome ≤ 12 months requiring dual antiplatelet therapy.\n6. Chronic liver disease (Child-Turcote-Pugh score ≥5) or chronic kidney disease stages 4-5 (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²).\n7. History of malignancy (except cured basal cell carcinoma).\n8. Moderate to severe anemia, polycythemia vera, or any hyperviscosity syndrome.\n9. Planned lower limb revascularization or amputation.\n10. Concurrent or planned use of medicinal products containing Veratrum species.\n11. Pregnant or lactating women, or women of childbearing potential not using highly effective contraception.\n12. Known allergy or hypersensitivity to any component of the study medication (Qilong Capsules, aspirin).\n13. Patients with psychiatric disorders or judged to be uncooperative.\n14. Currently participating in another drug clinical trial or using therapies with similar purported effects.\n15. Any other condition deemed by the investigator to make the participant unsuitable for the trial.","70 Years",{"count":278,"type":21},300,[165],"The goal of this clinical trial is to learn if adding a Traditional Chinese Medicine formula, Bu Yang Huanwu Decoction (specifically the capsule form called Hua Yu Wan Capsule), to standard treatment can help prevent leg pain at rest or foot ulcers in people with diabetic lower extremity vascular disease. The main questions it aims to answer are:\n\nDoes adding Hua Yu Wan Capsule to standard treatment lower the chance of developing leg pain at rest or foot ulcers after one year, compared to standard treatment alone?\n\nIs the treatment combination safe for participants?\n\nResearchers will compare two groups:\n\nGroup 1 (Experimental): Standard treatment (including aspirin, and medicines for blood sugar and cholesterol control) plus Hua Yu Wan Capsule.\n\nGroup 2 (Control): Standard treatment alone.\n\nParticipants in this study will:\n\nBe adults aged 18 to 70 years with diabetes and early to moderate lower extremity vascular disease (confirmed by tests like the Ankle-Brachial Index or ABI).\n\nBe randomly assigned to one of the two treatment groups.\n\nTake their assigned treatment for 6 months.\n\nAttend clinic visits at 1, 3 and 6 months during treatment, and again at 6 and 12 months after treatment ends for check-ups and tests.",[28,282,283],"Diabetic Angiopathies","Arterial Occlusive Diseases",[28,285,286,287],"Ischemia","Medicine, Chinese Traditional","Randomized Controlled Trial","2026-06-15",{"date":290,"type":43},"2026-06-22",{"date":149,"type":21},{"date":293,"type":21},"2029-01",{"name":295,"class":74},"Xuanwu Hospital, Beijing",{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100622588","a-single-arm-trial-to-evaluate-the-safety-and-efficacy-of-the-long--150mm-passeotm-18-luxtm-drug-coated-balloon-in-the-treatment-of-subjects-with-infrainguinal-stenotic-restenotic-or-occlusive-lesions-100622588","NCT07385573","A Single Arm Trial to Evaluate the Safety and Efficacy of the Long (> 150mm) PasseoTM-18 LuxTM Drug-coated Balloon in the Treatment of Subjects With Infrainguinal Stenotic, Restenotic or Occlusive Lesions","LUX-PAD","Inclusion Criteria\n\n* Study participant is ≥ 18 years and ≤ 99 years old\n* Lesion(s) in the infrainguinal arteries:\n\n  * Lesion above the knee (ATK): Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)\n  * Lesion below the knee (BTK): Target lesions involve arteries below the tibial plateau\n* RVD 2-7mm\n* De novo stenotic, restenotic post POBA, or occlusive lesion(s)\n* Target lesion must have angiographic evidence of ≥70% stenosis\n* Lesion length ≥ 3cm\n* Successful crossing of the target lesion with the guide wire\n* Successful predilatation, defined as residual stenosis \\\u003C50% Rutherford Class 2-5\n* Study participant is able to provide consent and has signed and dated the informed consent form\n\nExclusion criteria\n\n* Life expectancy ≤ 1 year\n* Study participant is currently participating in another investigational drug or device study that has not reached its primary endpoint yet.\n* Study participant is pregnant, planning to become pregnant, or father children during the course of the study.\n* Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion).\n* Prior bypass surgery of target vessel\n* Planned major amputation of the target limb\n* Thrombus in the target vessel\n* Known allergy to contrast media that cannot be adequately controlled with premedication\n* Study participant has a single target lesion that involves both ATK and BTK segments",{"count":304,"type":21},200,[24],"This clinical trial will evaluate the study device, Passeo®-18 Lux® paclitaxel-releasing percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of new or recurring cholesterol-related blockages in the arteries of the lower leg.\n\nThe device that is used in this trial has been assessed in several previous studies for safety and effectiveness. The device is already approved for use in Europe. It has a \"CE mark,\" which means it meets the European Union's safety, health and performance standards.\n\nThis trial is being done to gather additional information on how well the device works and how safe it is when used in everyday medical care with specific attention to the longer lengths of the balloon, as it comes in different sizes.",[308,28],"Drug Coated Balloon",[301,310,311],"Passeo-18 Lux Long","Passeo-18","2026-06-08",{"date":314,"type":43},"2026-06-09",{"date":149,"type":21},{"date":317,"type":21},"2032-01",{"name":319,"class":74},"KANDO Research",{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":326,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":329,"conditions":330,"keywords":341,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":363},"100618724","case-specific-health-care-professional-clinical-survey-of-liberant-thrombectomy-system-100618724","NCT07335341","Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System","Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:\n\n1. Patient treated is age ≥ 22 years at the time of procedure\n2. Use of Liberant in accordance with the device labeling within 72 hours of index procedure","22 Years",{"count":328,"type":21},50,"The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems",[331,332,333,334,335,336,337,28,338,339,340],"Venous Embolism of Lower Extremities (Diagnosis)","Arterial Embolism and Thrombosis","Acute DVT of Lower Extremity","Chronic DVT of Lower Extremity","DVT","Deep Vein Thrombosis Leg","Thrombus in the Peripheral Venous Vasculature","Acute Limb Ischemia","Lower Extremity Acute Limb Ischemia","LE ALI",[342,343,344,345,346,347,283,348,194,28,349,350,351,352,353,354],"Thrombus in Peripheral Arterial Systems","Thrombectomy","Thrombosis","Venous Thrombosis","Aspiration Thrombectomy","Percutaneous Mechanical Thrombectomy","Vascular Diseases","Mechanical Thrombectomy","Aspiration","Liberant Thrombectomy System","adverse events","Excipio","Thrombus in Peripheral Venous Systems","2026-06-05",{"date":312,"type":43},{"date":358,"type":43},"2026-02-24",{"date":360,"type":21},"2026-10",{"name":362,"class":50},"Medtronic Endovascular",2,{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":22,"phases":374,"briefSummary":375,"conditions":376,"keywords":377,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":188},"100540802","the-golazo-peripheral-atherectomy-system-for-a-safe-and-effective-atherectomy-great-trial-100540802","NCT06321575","The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)","The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy","GREAT","General inclusion criteria:\n\n1. Age ≥18 years\n2. Candidate for atherectomy of the peripheral vasculature in the lower limbs\n3. Life expectancy \\>1 year in the opinion of the investigator\n4. Resting ankle brachial index (ABI) ≤0.90, or ≤0.75 after exercise. Subjects with non-compressible arteries shall have a toe brachial index (TBI) assessment.\n5. Target limb Rutherford clinical classification category 3 to 5\n6. Suitable candidate for angiography and endovascular intervention in the opinion of the investigator\n7. Willing and able to comply with the protocol-specified procedures and assessments\n8. Informed consent granted\n\n   Angiographic inclusion criteria:\n9. Target lesion(s) defined as stenosis ≥70% by angiographic visual estimation\n10. Total treated lesion length ≤20 cm by angiographic visual estimation\n11. Target reference vessel diameter (RVD) ≥2.0 mm and ≤4.5 mm by angiographic visual estimation\n12. Target limb will have a minimum of one patent (less than 50% stenosis) below the knee (BTK) vessel crossing the ankle, distal to any target lesion, providing perfusion to the foot at baseline\n\nGeneral exclusion criteria:\n\n1. Active infection in the target limb\n2. History of an endovascular procedure or open vascular surgery on the target limb within the last 30 days\n3. Planned surgical or interventional procedure within 30 days after the index procedure\n4. Lesion in the contralateral limb requiring intervention during the index procedure or within next 30 days\n5. Critical limb ischemia (CLI) with Rutherford clinical classification category 6\n6. Significant acute or chronic kidney disease with a GFR \\\u003C30 and\u002For requiring dialysis\n7. Acute myocardial infarction (non-ST-elevation myocardial infarction or ST-segment elevation myocardial infarction) or other uncontrolled comorbidity in the opinion of the investigator\n8. Myocardial infarction (MI) or stroke within two months of baseline evaluation\n9. Pregnant or lactating\n10. Subject is participating in another clinical investigation of a device, drug, or procedure that has not completed the study treatment or that clinically interferes with the endpoints of this study (post-approval registries are allowed as long as the investigator determines there is no clinical interference with study endpoints)\n11. Contraindication to antiplatelet, anticoagulant, or thrombolytic therapy\n12. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count \\\u003C125,000\u002Fmicroliter, known coagulopathy, or international normalized ratio (INR) \\>1.5\n13. Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately medicated\n14. History of heparin-induced thrombocytopenia (HIT)\n15. Any thrombolytic therapy within two weeks of enrollment\n16. Target lesion(s) within a native vessel graft or synthetic graft\n17. Significant stenosis or occlusion of inflow not successfully treated before the index procedure\n18. Any evidence or history of intracranial or gastrointestinal bleeding or intracranial aneurysm\n19. Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults)\n20. One or more of the following complications of the foot:\n\n    1. Osteomyelitis that extends to the metatarsal bones.\n    2. Gangrene involving the plantar skin of the forefoot, midfoot or heel\n    3. Deep ulcer or large shallow ulcer (\\>3cm) involving the plantar skin of the forefoot, midfoot, or heel\n    4. Any heel ulcer with\u002Fwithout calcaneal involvement\n    5. Any wound with calcaneal bone involvement\n    6. Wounds that are deemed to be neuropathic or non-ischemic in nature\n    7. Wounds that require flap coverage or complete wound management for large soft tissue defect\n21. Congestive heart failure with a NYHA functional classification of III or higher\n\n    Angiographic exclusion criteria:\n22. More than 2 lesions to be treated with the investigational device; lesions located within 3 mm may be considered a single tandem lesion\n23. Clinical\u002Fangiographic complication (other than non-flow limiting dissections) attributed to a currently marketed device prior to introduction of the investigational device\n24. In-stent restenosis within the target lesion(s)\n25. Potentially unstable or flow-limiting dissection, type C or greater\n26. Clinical\u002Fangiographic evidence of distal embolization\n27. Inability to cross the proximal lesion vessel lumen with a guidewire (not subintimal)",{"count":373,"type":21},159,[24],"The objective of this study is to establish reasonable assurance of safety and effectiveness of the Golazo® Peripheral Atherectomy System when used as indicated in 159 subjects with symptomatic infrainguinal peripheral arterial disease (PAD) in up to 20 investigational sites in the U.S.",[28],[378,379],"Symptomatic Infrainguinal Peripheral Arterial Disease","Endovascular Intervention","2026-06-04",{"date":355,"type":43},{"date":383,"type":43},"2024-06-20",{"date":385,"type":21},"2026-11",{"name":387,"class":50},"Avantec Vascular",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":395,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":405,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":417,"leadSponsor":419,"locationsCount":100},"100640379","in-hospital-wearable-based-monitoring-versus-standard-care-in-cardiovascular-disease-inspire-100640379","NCT07622485","In-Hospital Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease (INSPIRE)","In-Hospital Efficacy and Safety of Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease: A Stepped-Wedge Cluster Randomized Controlled Trial (INSPIRE Trial)","Inclusion Criteria:\n\nAdults aged 20 years or older\n\n* Hospitalized for cardiovascular disease, with at least one of: acute coronary syndrome; chronic coronary syndrome; acute heart failure (NYHA class III-IV or acute decompensated heart failure); arrhythmia (atrial fibrillation, ventricular tachycardia, complete AV block, or other clinically significant arrhythmia); peripheral arterial or aortic disease; post-cardiovascular-procedure observation (PCI, CABG, valve surgery, or electrophysiology study); or thromboembolic disease\n* Able to provide written informed consent\n* Able to wear the wearable monitoring device\n\nExclusion Criteria:\n\n* Hemodynamically unstable shock (sustained systolic blood pressure \\\u003C 90 mmHg requiring vasopressors; cardiogenic shock; septic shock)\n* Planned or current intensive care unit admission\n* Within 24 hours after cardiopulmonary resuscitation\n* Physical condition precluding device wearing (bilateral upper-limb amputation; severe skin lesion, burn, or open wound at the device site; known allergy to device materials)\n* Severe cognitive impairment or delirium precluding informed consent Extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pump (IABP) in use\n* Continuous renal replacement therapy (CRRT) in use (patients on CRRT may participate if hemodynamically stable and device wearing is technically feasible)\n* Unable to communicate in Korean for study explanation and the consent process\n* Previously enrolled in this study (re-admitted patients are not re-enrolled; each participant is enrolled only at the first admission)\n* Considered inappropriate for participation by the investigator","20 Years",{"count":397,"type":21},1500,[24],"Patients hospitalized with cardiovascular disease require timely detection of clinical deterioration to prevent adverse outcomes. Standard inpatient care relies on intermittent nursing vital-sign measurements performed every 4 to 8 hours, which can miss hemodynamic or arrhythmic events occurring between measurements. This trial evaluates whether digital wearable-based monitoring - wireless continuous measurement of vital signs and electrocardiography with a real-time alerting system - reduces major adverse cardiovascular events (MACE) compared with standard intermittent monitoring in patients hospitalized for cardiovascular disease. The trial uses a stepped-wedge cluster-randomized design in which four inpatient ward zones (clusters) are sequentially transitioned from standard care to wearable monitoring over five periods.",[401,402,403,404,28],"Cardiovascular Diseases","Acute Coronary Syndrome","Heart Failure","Cardiac Arrhythmia",[406,407,408,409,410,411,412],"wearable device","continuous monitoring","remote monitoring","stepped-wedge cluster trial","major adverse cardiovascular events","digital health","inpatient monitoring","2026-06-01",{"date":415,"type":43},"2026-06-03",{"date":40,"type":21},{"date":418,"type":21},"2029-12-31",{"name":420,"class":74},"Yonsei University",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":445,"leadSponsor":447,"locationsCount":100},"100618804","shortwave-diathermy-in-home-treatment-for-indianapolis-va-only-patients-diagnosed-with-peripheral-artery-disease-and-peripheral-neuropathy-100618804","NCT07336381","Shortwave Diathermy In-home Treatment for Indianapolis VA-only Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy","An Exploratory Clinical Study Using the Replexa+ Device in Veterans With Lower Extremity Peripheral Artery Disease Experiencing Peripheral Neuropathy","Replexa+","Inclusion Criteria:\n\n1. Diagnosis of peripheral artery disease (PAD).\n2. Participants must exhibit PAD severity, defined by the following manifestation and corresponding Rutherford classifications:\n\n   Claudication of the index limb (Rutherford Category 2 or 3- documented as pain with walking) in conjunction with one or more of the following:\n   * ankle brachial index (ABI) greater than or equal to 0.6 mmHg, as measured no more than 6 months prior to screening\n   * resting toe brachial index (TBI) greater than or equal to 0.4, as measured no more than 6 months prior to screening\n\n   Note: In cases where ankle and toe systolic pressures are unavailable due to calcification and\u002For toe amputation, collection of angiographic data is acceptable to determine locations of blockages or reduced perfusion.\n3. Diagnosis of peripheral neuropathy, as evidenced by review of medical records.\n4. Competent to give consent.\n5. Age 18 years or older.\n\nExclusion Criteria:\n\n1. Impaired skin integrity in the location(s) to be treated.\n2. Current wounds or ulcerations.\n3. Diagnosis of active bleeding tendencies, hemorrhage, or thrombosis.\n4. 2+ pitting edema in either lower extremity.\n5. Active infection defined as elevated white blood cell count \\>11,500\u002FµL or fever \\>101.5 degrees Fahrenheit or currently taking antibiotic medication(s) for an active infection.\n6. Existence of metal hardware in the area(s) to be treated: Any patient with implanted electronic or metal device such as a pacemaker, bladder stimulator, spinal cord stimulator or electrodes for a myoelectric prosthesis, IUD, surgical staples or implanted metallic leads.\n7. Pregnant individuals.\n8. Presence of renal disease (creatinine \\> 2.5 mg\u002Fdl and estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin) or patients on chronic hemodialysis.\n9. History of skeletal tuberculosis.\n10. Patients, in the investigator's opinion, whose index limb condition is rapidly deteriorating and may require major amputation within 30 days of screening.\n11. Conditions that impair cognitive function.\n12. Severe concomitant disease(s), or any additional condition(s) which the investigator feels constitute(s) criteria for exclusion of a particular subject.",{"count":430,"type":21},10,[24],"This research project is designed to see if treatment with the Replexa+ shortwave diathermy device daily for 3 months will improve blood flow in the lower legs and feet of patients diagnosed with peripheral artery disease and peripheral neuropathy.",[28,434],"Peripheral Neuropathy",[436,437,438,439,440],"peripheral artery disease","peripheral neuropathy","lower extremity artery disease","lower extremity neuropathy","PAD","2026-05-27",{"date":443,"type":43},"2026-05-29",{"date":40,"type":21},{"date":446,"type":21},"2027-12-31",{"name":448,"class":74},"Indiana University",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":469},"100501600","the-gore-vbx-forward-clinical-study-a-comparison-of-the-gore-viabahn-vbx-balloon-expandable-endoprosthesis-to-bare-metal-stenting-for-patients-with-complex-iliac-occlusive-disease-100501600","NCT05811364","The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease","Inclusion Criteria:\n\n* Age ≥ 18 years at time of informed consent signature\n* Informed Consent Form (ICF) is signed by the subject\n* Subject can comply with protocol requirements, including follow-up\n* Patient has symptomatic claudication, rest pain, or minor tissue loss (Rutherford Category 2-5)\n* Patient has de novo or restenotic lesion(s) found in the common and\u002For external iliac artery(ies)\n* Patient has: Unilateral or bilateral single or multiple lesions (\\>50% stenosis or chronic total occlusion) each between 4 and 11 cm in length\n* Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm\n* Patient has a sufficient (\\\u003C50% stenotic) common femoral artery and at least one sufficient (\\\u003C50% stenotic) femoral artery (deep or superficial).\n* Patient has at least one sufficient (\\\u003C50% stenotic) infrapopliteal run-off vessel.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year\n* Patient is pregnant at time of informed consent.\n* Patient has a known allergy to stent or stent graft components (including nitinol, stainless steel, or heparin).\n* Patient has severe chronic renal insufficiency (serum creatinine level \\> 2.5mg\u002FdL) and not undergoing hemodialysis.\n* Patient has evidence of a systemic infection.\n* Patient has a known intolerance to antithrombotic medications that prevent compliance with study or control device Instructions for Use.\n* Patient has had vascular catheterization of the lower extremities within 30 days of randomization (excluding diagnostic angiograms for the study procedure).\n* Patient has previous stenting in the iliac arteries.\n* Patient has previous surgical bypass in the target limb.\n* Patient is currently participating in another investigative clinical study unless received written approval by the sponsor.\n* Patient has a lesion requiring drug-coated balloon angioplasty, atherectomy, lithotripsy, or any ablative device to facilitate stent delivery.\n* Patient has an abdominal aortic artery lesion or aneurysm.\n* Patient has a lesion that requires stent placement within 2 cm of the inguinal ligament.\n* Patient has isolated common iliac artery stenosis that can be treated with a single device (i.e., common iliac artery stenosis that does not require kissing stents or extend into the external iliac artery).\n* Patient has outflow disease that requires concomitant interventions (i.e. common femoral endarterectomy or femoral \u002F tibial revascularization).",{"count":456,"type":21},244,[24],"The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.",[113,28],"2026-05-11",{"date":462,"type":43},"2026-05-13",{"date":464,"type":43},"2023-10-17",{"date":466,"type":21},"2032-01-31",{"name":468,"class":50},"W.L.Gore & Associates",43,{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":22,"phases":480,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":491,"locationsCount":4},"100541157","phase-1-cell-therapy-for-lower-limb-ulcers-in-patients-with-critical-limb-ischemia-100541157","NCT06326203","Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia","Randomized, Prospective, Controlled, Single-center, Open-label Phase II Clinical Trial Aimed at Evaluating the Safety and Efficacy of Autologous Mesenchymal Stem Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia","Inclusion Criteria:\n\n* Absence of distal pulses in the leg (anterior tibial and posterior tibial) and presence or absence of popliteal pulse.\n* Peripheral Arterial Disease (PAD).\n* Having foot or leg ulcer(s) (distal third) with a minimum area of 1cm2 and a maximum of 3 ulcers totaling up to 20cm2 in the lower limb.\n* Having previously received conventional dressing treatment for ulcer indicating no improvement over a minimum period of 3 weeks (antibiotic therapy - if necessary - local care such as mechanical, surgical or chemical debridements - if necessary, dressings).\n* PAD with IC classified as Fontaine IV and Rutherford 5.\n* Having Ankle Brachial Index (ABI) \\\u003C0.9 in infragenicular arteries (anterior tibial, posterior tibial, and fibular) or ABI\\>1.3 in one or more infragenicular arteries when suffering from chronic DMT2 (disease duration \\> 5 years) not subjected to revascularization treatment or subjected to partial revascularization treatment or treatment failure (stenosis or occlusion) in the last 12 months.\n* Inability to revascularize the affected limb (do not have visible infragenicular arteries for surgical approach) and or incomplete revascularization of this limb (undergone endovascular and or surgical treatment that was not able to restore infragenicular pulses) and defined by the doctor that the best available treatment from the surgical vascular point of view has already been performed and was not successful in promoting ulcer healing.\n* Drug treatment for PAD and for comorbidities.\n* Availability to attend medical appointments.\n\nExclusion criteria:\n\n* Being pregnant or in the puerperium.\n* Having a healed ulcer during the screening period.\n* Having signs of systemic infection or active infection in the arterial ulcer or infection of surgical prostheses (bypass, pins, screws). They may be eligible again if they have been successfully treated with antibiotics and the infectious focus has been removed.\n* Having an ulcer with devitalized tissue (necrosis). They may be eligible again if they have undergone successful surgical debridement or minor amputations (amputation of toes or limited to the forefoot).\n* Having neoplasia and\u002For being in chemotherapy or radiotherapy treatment or in remission for less than 6 months.\n* Being on colchicine or immunomodulators.\n* Having infectious diseases such as Human Immunodeficiency Virus (HIV), Hepatitis B and C viruses, Human T-cell Lymphotropic Virus (HTLV); due to the risk of contagion during the manipulation of biological material in the laboratory.\n* Having undergone amputation at the level of the leg or thigh in the limb intended to be studied.\n* Having COVID-19, diagnosed less than 4 weeks ago.","90 Years",{"count":479,"type":21},40,[139,481],"PHASE2","Peripheral arterial disease (PAD) can progress to critical limb ischemia (CLI) of the affected lower limb, characterized by pain at rest, ulcerations or gangrene, with a high risk of amputation. In this phase, the best treatment is arterial limb revascularization, but this is not always possible or even effective for promoting pain relief, healing of ulcers or preventing amputations, in addition to the high socioeconomic cost caused by the disease. Recent advances in cell therapy represent a promising supporting alternative for the treatment of PAD in cases where conventional alternatives have run out. Objective: To evaluate the safety and efficacy of cell therapy with expanded autologous mesenchymal stem cells in the treatment of patients with PAD with CLI and chronic arterial ulcers. Methods: An open randomized clinical study will be performed with 2 groups of 20 patients with CLI: in group 1, a fragment of abdominal fat tissue (10g) will be collected to obtain mesenchymal stem cells, which will be expanded and applied using subcutaneous perilesional injection in the affected lower limb, in addition to the application in the form of a personalized curative biological on the wounds. Group 2 will receive conventional treatment with a Hydrogel dressing with essential fatty acids. Periodic clinical evaluations, complementary exams and photographic record will be carried out. The main outcome of effectiveness will be partial or total wound healing. Safety outcomes will be monitored for infections, gangrene, amputations and deaths. Participants will be monitored for 120 days. Major amputation cases will not be included. An independent external evaluator and blind to the groups will evaluate the results. It is an innovative procedure with high impact and financial return for SUS, in view of the high prevalence of the disease and the high socioeconomic impact of the disease when it progresses to limb amputation.",[28,484],"Leg Ulcer","2026-05-04",{"date":487,"type":43},"2026-05-06",{"date":413,"type":21},{"date":490,"type":21},"2028-03-31",{"name":492,"class":74},"UPECLIN HC FM Botucatu Unesp",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":503,"briefSummary":504,"conditions":505,"keywords":506,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":100},"100524702","comparison-of-a-lithotripsy-vs-standard-preparation-followed-by-stenting-with-supera-stent-in-femoropopliteal-lesions-100524702","NCT06112171","Comparison of a Lithotripsy vs Standard Preparation Followed by Stenting With Supera Stent in Femoropopliteal Lesions","Performance of the Shockwave Medical Peripheral Lithotripsy System vs Standard Balloon Angioplasty for Lesion Preparation Prior to Supera Stent Implantation in the Treatment of Symptomatic Severely Calcified Femoropopliteal Lesions in PAD","CRACK-IT","Inclusion Criteria:\n\n* Subject age ≥ 18\n* Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved inform consent form\n* Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing\n* Rutherford Classification 2-5\n* Subject has a de novo or restenotic lesion in SFA and\u002For PPA not exceeding the medial femoral epicondyle with ≥ 70% stenosis documented angiographically\n* No previous stent in the target lesion, if target vessel was previously stented the stent should be at least 3cm apart\n* Target lesion length is ≥ 10cm, no maximum lesion length limit\n* Severe calcification on fluoroscopy defined by PACSS Grade 4: 1) bilateral calcification and 2) extending ≥50mm in length\n* Multiple lesions with max. 3cm healthy vessel segment in between lesions can be considered at the discretion of the operator as one lesion\n* Reference vessel diameter (RVD) ≥ 4 mm and ≤ 6.5 mm by visual estimation\n* Patency of at least one infrapopliteal artery to the ankle (\\\u003C 50% diameter stenosis) in continuity with the native femoropopliteal artery\n* A guidewire has successfully traversed the target treatment segment (both intraluminal and subintimal crossing allowed)\n\nExclusion Criteria:\n\n* Failure to successfully cross the target lesion\n* Presence of fresh thrombus in the lesion\n* Presence of aneurysm in the target vessel\u002Fs\n* Presence of a stent in the target lesion, at least 3cm from any previously stent in target vessel\n* Prior vascular surgery of the target lesion\n* Stroke or heart attack within 3 months prior to enrollment\n* Enrolled in another investigational drug, device or biologic study that has not reached the primary endpoint\n* Life expectancy of less than one year\n* Known allergies or sensitivity to heparin, aspirin, other anticoagulant\u002F antiplatelet therapies or contrast media that cannot be adequately pre-treated prior to index procedure\n* Rutherford Classification of 0, 1, or 6\n* Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy\n* Receiving immunosuppressant therapy\n* Pregnant or breast-feeding females\n* History of major amputation (defined as amputation above ankle joint) in the same limb as the target lesion",{"count":502,"type":21},120,[24],"This study is an investigator-initiated, prospective, single-center, 1:1 randomized pilot study.\n\nThe trial evaluates the safety and efficacy of intravascular lithotripsy in comparison to standard lesion preparation using standard and\u002For high-pressure balloon angioplasty in patients with femoropopliteal artery disease. All patients will receive subsequent Supera stent implantation at the operator's discretion. Additional standard nitinol bare metal stent (BMS), drug-eluting stent or covered stent implantation is at the operator's discretion.\n\nPatients will be stratified for total occlusions.",[28],[507,508],"Calcification","Lithotripsy","2026-04-30",{"date":487,"type":43},{"date":512,"type":43},"2024-02-13",{"date":514,"type":21},"2032-12-31",{"name":516,"class":74},"University of Leipzig",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":134,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":526,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":100},"100589294","ultrasound-perfusion-estimation-for-assessment-of-peripheral-arterial-disease-100589294","NCT06952543","Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease","Ultrasound Perfusion Estimation for Assessment of PAD","Inclusion Criteria:\n\nPatient volunteers:\n\n* Male and Female, ages 18 years old and up\n* Symptom of claudication and suspected for PAD\n* Scheduled for vascular testing.\n\nHealthy volunteers:\n\n* Male and female, ages 18-75 years old and up\n* Normal BMI\n* No history of smoking, cardiovascular disease, or diabetes.\n\nExclusion Criteria:\n\nPatient volunteers:\n\n* Patients with gangrene\n* Patients having surgery or stent\n* Patients with ulcer on their leg\n* Any health condition that does not allow proper use of ultrasound scanning\n* People considered in \"vulnerable\" populations.\n\nHealthy volunteers:\n\n* Include volunteers with BMI not more than 30\n* No history of smoking\n* No history of (diabetes, hypertension, cardiovascular diseases)\n* People considered in \"vulnerable\" populations.",{"count":525,"type":21},400,[24],"The purpose of this study is to develop a new noninvasive tool for early diagnosis of Peripheral Arterial Disease (PAD) and use the proposed method for monitoring the disease progression and the response to interventional treatment in PAD patients.",[28],"2026-04-29",{"date":531,"type":43},"2026-05-05",{"date":533,"type":43},"2025-03-14",{"date":535,"type":21},"2029-08-30",{"name":537,"class":74},"Mayo Clinic",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":22,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":553,"leadSponsor":555,"locationsCount":100},"100610119","revasc-pad-restricted-vascular-exercise-for-peripheral-arterial-disease---a-feasibility-study-at-university-of-tennessee-medical-center-100610119","NCT07223437","REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennessee Medical Center","REVASC-PAD","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Diagnosed peripheral arterial disease with stable claudication (symptomatic presentation unchanged for 6 months)\n3. Ankle-brachial index (ABI) between 0.4 and 0.9.\n4. Eligible referral to cardiovascular or pulmonary rehabilitation\n5. Prior revascularization permitted if symptoms are stable and other criteria are met\n\nExclusion Criteria:\n\n1. Recent change in resting ECG suggesting significant ischemia, recent myocardial infarction (within 2 weeks), or another acute cardiac event\n2. Unstable angina\n3. Uncontrolled cardiac arrhythmias\n4. Symptomatic severe aortic stenosis or other significant valvular disease\n5. Decompensated symptomatic heart failure\n6. Acute pulmonary embolism or infarction\n7. Acute noncardiac disorder likely to interfere with or be worsened by exercise (e.g., infection, thyrotoxicosis)\n8. Acute myocarditis or pericarditis\n9. Acute thrombophlebitis\n10. Physical disability precluding safe or adequate exercise performance\n11. Significant electrolyte abnormalities\n12. Clinically significant tachyarrhythmias or bradyarrhythmias\n13. High-degree atrioventricular block\n14. Atrial fibrillation with uncontrolled ventricular response\n15. Hypertrophic obstructive cardiomyopathy with resting left ventricular outflow gradient of \\>25 mmHg\n16. Known active aortic dissection\n17. Severe resting arterial hypertension (SBP\\>200mmHg or DBP \\>110 mmHg)\n18. Mental impairment preventing cooperation with study procedures\n19. Current pregnancy\n20. Moderate to severe peripheral neuropathy\n21. Open wounds or compromised skin near BFR cuff site\n22. Active DVT or thromboembolic event within the past year",{"count":546,"type":21},81,[24],"The purpose of this study is to evaluate the effects of Blood Flow Restriction (BFR) training on walking function, health-related quality of life, and safety among adults with Peripheral Arterial Disease (PAD).\n\nThe main aims of the study are:\n\n1. Evaluate change in walking function among patients with PAD undergoing BFR training. The investigators will assess change in Six-Minute Walk Test (6MWT) distance from baseline to post-intervention and 3-month follow-up to compare functional improvements between the BFR group and the two control groups\n2. Assess changes in health-related quality of life among patients with PAD undergoing BFR training. The investigators will use the EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale to evaluate quality-of-life changes from baseline to post-intervention and 3-month follow-up across all study arms\n3. Evaluate the safety and feasibility of a supervised BFR training program for patients with PAD. The investigators will compare adverse event (AE) and serious adverse event (SAE) rates across study arms, while also monitoring sessional ratings of perceived exertion (RPE), dyspnea, and claudication pain as indicators of symptom response and exercise tolerance. Feasibility will be assessed through enrollment success, intervention adherence, and retention rates across groups",[28],"2026-04-27",{"date":529,"type":43},{"date":550,"type":43},{"date":554,"type":21},"2027-04-27",{"name":556,"class":74},"University of Tennessee Graduate School of Medicine",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":566,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":578},"100443507","selution4btk-trial-100443507","NCT05055297","SELUTION4BTK Trial","SELUTION SLR™ 014 BTK: A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR™ 014 Drug Eluting Balloon in the Treatment of Below-the-Knee (BTK) Atherosclerotic Disease in Patients With Chronic Limb Threatening Ischemia (CLTI)","Clinical Inclusion Criteria:\n\n1. Subject age is ≥ 18 years or older depending on local regulations.\n2. Subject life expectancy is ≥ 1 year.\n3. Subject has documented chronic limb-threatening ischemia in the target limb with Rutherford classification category 4 or 5 and symptoms of \\> 2 weeks duration.\n4. Subject is willing and able to provide written informed consent and comply with study procedures and required follow-up evaluations.\n5. Female subjects of childbearing potential must be non-breastfeeding and have a negative pregnancy test ≤ 7 days before the procedure.\n\nAngiographic Inclusion Criteria:\n\nSubjects must meet all the following criteria to be enrolled in the trial:\n\n1. Target lesion(s) must be de novo or non-stented restenotic lesion(s) located within the BTK arteries distal to the tibial plateau and above the tibiotalar joint line. BTK arteries include the P3 segment of the popliteal artery, the tibio-peroneal trunk, peroneal artery, anterior tibial artery, and posterior tibial artery.\n2. BTK Target lesions cannot be contiguous with inflow lesions and at least 3 cm of normal artery should extend beyond the tibial plateau to ensure there is no overlap.\n3. Target lesions must have a diameter stenosis of ≥ 70% (including total occlusions) by visual estimate and must be indicated for PTA treatment.\n4. Target vessel reference diameter(s) are ≥ 2mm and ≤ 4mm. Note: the SELUTION SLR 014 DEB and the control PTA balloon size cannot exceed 4.0 mm.\n5. Target lesions must be confined to a single target vessel. NOTE: Subjects with other non-target BTK lesions in separate non-target vessels may be enrolled, provided that the non-target lesions have been successfully treated (residual stenosis ≤ 30% with no distal embolization or flow limiting ≥ Grade C dissection). NOTE: Any adjunctive therapies are permitted for the treatment of non-target BTK lesions, but no DEB or DES may be used.\n6. Any target lesion must be ≥ 30 mm in length and the total combined length of all target lesions must be ≤ 140 mm (total treatment length ≤ 150 mm allowing for 5 mm proximal and distal shoulder treatment). Note: All target lesions and all inflow lesions must be treatable by one or more SELUTION SLR 014\u002F018 DEB(s) such that the total planned per-subject drug dose (calculated by summing the drug dose of all individual planned balloon sizes) would be ≤ 7069 μg. Note: A total treated segment length of ≤ 150 mm for BTK and ≤ 200 mm for inflow segment is acceptable irrespective of DEB balloon diameter.\n7. The tibial and pedal runoff distal to the target lesions must be patent OR the target vessel(s) must reconstitute above the ankle or display normal terminal branching as follows:\n\n   1. If the target vessel is the P3 segment, any 1 of the 3 distal arteries must show a patent (≤ 50% stenosis by visual estimate) outflow.\n   2. If the target vessel is the peroneal artery, the artery must demonstrate normal terminal branching.\n   3. If the target vessel is the anterior tibial (AT) or posterior tibial (PT) artery, the artery must reconstitute ≥ 1 cm above the tibiotalar joint to provide an intact runoff vessel (AT: dorsalis pedis; PT: plantar artery).\n   4. If the target vessel is the tibio-peroneal trunk, outflow for either the peroneal OR the posterior tibial artery must be patent (≤ 50% stenosis by visual estimate).\n8. Subjects is free of significant inflow vessel disease or any inflow disease has been successfully treated (see angiographic inclusion # 9). Significant inflow disease is defined as ≥ 50% stenosis by visual estimate. Inflow vessels include the ipsilateral common iliac, external iliac, common femoral, profunda femoris, superficial femoral or popliteal artery proximal (≥ 3 cm) to the tibial plateau. Note: If access site doesn't permit angiographic imaging of the common iliac and common femoral artery (CFA), then non-invasive imaging (CTA or MRA) must be provided to exclude presence of significant inflow disease. If non-invasive imaging is not possible, a DUS of the CFA with a multiphasic wave form excluding significant disease AND a palpable ipsilateral femoral pulse must be documented.\n9. Subjects with significant inflow disease (≥ 50% stenosis by visual estimate) must have documented successful treatment before randomizing the subject. Successful treatment of inflow disease is defined as ≤ 30% final residual stenosis and no distal embolization or flow-limiting \\> Grade C dissection. Note: Treatment of the common femoral and profunda femoris is not permitted. Inflow vessel treatment can be performed with any commercially available non-DCB or non-DES device; if DCB treatment is required, SELUTION SLR 018 must be used.\n10. The BTK target lesion preparation must be documented to be successful by angiography (≤ 30% residual stenosis and no distal embolization or flow-limiting ≥ Grade C dissection) before randomization. Note: Lesion preparation can include atherectomy (rotational, orbital, directional or laser), cutting, scoring, contoured balloons or intravascular lithotripsy and PTA only.\n\nClinical Exclusion Criteria:\n\nSubjects will be excluded if any of the following criteria apply:\n\n1. Subject has extensive tissue loss (Rutherford category 6) extending above the trans metatarsal level, salvageable only with complex foot reconstruction or non-traditional trans metatarsal amputations. This includes subjects with:\n\n   1. Osteomyelitis involving proximal to the metatarsal head(s)\n   2. Any heel wound or wound with calcaneal bone involvement\n\n   d) Wounds that would require flap coverage or complex wound management for large soft tissue defect e) Full-thickness wounds on the dorsum of the foot with exposed tendon or bone\n2. Subject has chronic renal insufficiency (dialysis dependent, or glomerular filtration rate \\[GFR\\] ≤ 30 ml\u002Fmin\u002F1.73 m2 within 30 days of index procedure) or has undergone renal transplantation.\n3. Subject has acute renal insufficiency confirmed by 50% increase of serum creatinine within 48 hours before procedure and\u002For decrease in urine output.\n4. Subject has acute limb ischemia with onset of index limb symptoms less than 2 weeks prior to index procedure.\n5. Subjects has wounds that are deemed to be neuropathic or non-ischemic in nature or any venous or mixed wounds.\n6. Subject has had prior major amputation of the ipsilateral extremity or planned major amputation of either leg.\n7. Target limb iliac or common femoral artery bypass within 6 weeks of index procedure.\n8. Prior (within 14 days) or planned (within 30 days) surgical or endovascular procedures. The following procedures are permitted:\n\n   1. Target limb inflow treatment at the index procedure, provided it meets the criteria in Angiographic Inclusion Criteria #12\n   2. Contralateral limb iliac artery treatment\n   3. Diagnostic angiography\n   4. Foot wound debridement\n   5. Planned minor amputation of digit(s) at the phalangeal level\n9. Target lesion has undergone prior DCB within 1 year, or ANY prior DES or bare metal stent (BMS) treatment (no in-stent restenosis \\[ISR\\] treatment is permitted). Note: Prior stent is permitted if the target lesion is located ≥ 30 mm from the stent AND there is ≤ 30% in-stent diameter stenosis.\n10. Target lesion(s) requires treatment with alternative therapies such as thrombolysis, thrombus aspiration, stenting, cryoplasty, brachytherapy, or re-entry device. Note: The following adjunctive lesion preparation therapies are permitted: Atherectomy (rotational, orbital, directional or laser), cutting\u002Fscoring\u002Fcontoured balloon, or intravascular lithotripsy.\n11. Target lesion requires treatment via pedal access or upper extremity access.\n12. Subject has undergone non-coronary artery treatment with any limus-based drug coated balloon (DCB) or DES or other device within 3 months prior to index procedure.\n13. Subject has known hypersensitivity or allergy to Sirolimus or other pharmacologic agents required for the procedure (such as contrast agent, heparin, bivalirudin) that cannot be adequately pre-treated.\n14. Subject has contraindication to antiplatelet therapy.\n15. Subject has experienced disabling stroke or ST-segment elevation myocardial infarction (STEMI) within 3 months of index procedure.\n16. Subject has acute coronary syndrome. Stabilized Acute Coronary Syndrome (ACS) is permitted.\n17. Subject has non-atherosclerotic disease of the target vessel (including aneurysmal disease and vasculitis) or Buerger's disease.\n18. Subject has hypercoagulable state or disorder, or coagulopathy, including platelet count ≤ 100,000 per microliter.\n19. Subject has systemic infection (White Blood Count \\[WBC\\] \\> 12,000 and febrile). \\[Note: Enrollment permitted after successful treatment of infection with resolution of leukocytosis and\u002For febrile state\\].\n20. Subject is known to be immune compromised (e.g., Human Immunodeficiency virus \\[HIV\\], Systemic Lupus Erythematosus \\[SLE\\]) or is receiving treatment with immune suppressive medications (NOTE: topical corticosteroids are permitted)\n21. Subject is receiving (or is scheduled to receive) cancer treatment with surgery or chemotherapy or radiation therapy or has metastatic malignancy. Note: local application of chemotherapeutic creams is allowed.\n22. Subject has New York Heart Association (NYHA) class IV congestive heart failure.\n23. Subject is bedridden.\n24. Subject has a body mass index (BMI) \\\u003C 18.\n25. Subject is currently participating in another investigational drug or device study that has not completed primary endpoint follow-up.\n26. Subject has other anatomic, medical, social, or psychological conditions that in the investigator's opinion could limit the patient's ability to participate in the clinical study and\u002For comply with the follow-up requirements.\n\nAngiographic Exclusion Criteria:\n\nSubjects will be excluded if any of the following criteria apply:\n\n1. Presence of a previously placed stent in the target vessel(s), UNLESS the target lesion is located ≥ 30 mm from the stent AND there is ≤ 30% in-stent diameter stenosis.\n2. There is significant (\\> 50% diameter stenosis) inflow disease in the common femoral and profunda femoris arteries (inflow treatment of the common femoral and profunda femoris is not permitted).\n3. The target lesion could not be successfully pre-dilated (residual stenosis \\> 30%, distal embolization, or flow-limiting ≥ Grade C dissection after pre-dilatation).\n4. Intra-arterial thrombus, thromboembolism or atheroembolism in the index limb noted on initial diagnostic angiography or following treatment of inflow disease or pre-treatment of target lesion.\n5. Subject requires treatment of the tibial arteries distal to the tibiotalar joint line, or treatment of the pedal arteries. Angioplasty at or below the tibiotalar joint is not permitted.",{"count":565,"type":21},376,[24],"This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.",[28,569],"Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities",{"date":571,"type":43},"2026-04-28",{"date":573,"type":43},"2022-05-19",{"date":575,"type":21},"2032-07-30",{"name":577,"class":50},"M.A. Med Alliance S.A.",48,{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":587,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":22,"phases":590,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":363},"100336696","handgrip-training-in-patients-with-peripheral-artery-disease-100336696","NCT03663777","Handgrip Training in Patients With Peripheral Artery Disease","Effects of 12 Weeks of Isometric Handgrip Training in Blood Pressure in Patients With Peripheral Artery Disease","Isopress_03","Inclusion Criteria:\n\n* Women in post-menopause phase without hormone replacement therapy\n* Ankle-brachial index \\\u003C0.90\n* Not severe obese (≥ 35kg\u002Fm2)\n* Not present amputation in the limbs\n* Have blood pressure levels lower than 160mmHg for systolic and 105mmHg for diastolic\n\nExclusion Criteria:\n\n* patients will only be excluded if they make any medication changes before completing the intervention period or present any health problems that prevent physical activity.","45 Years",{"count":589,"type":21},30,[24],"The aim of this study is to analyze the effects of isometric handgrip training (IHT) on blood pressure of hypertensive patients with peripheral arterial disease. Will be recruited 30 patients which will be randomized into 2 groups (15 per group), IHT and control group (CG). IHT group will training isometric contraction for 12 weeks. In CG patients will be encouraged to increase the level of physical activity. In the pre and post-intervention cardiovascular measures will be obtained.",[28],{"date":594,"type":43},"2026-05-01",{"date":596,"type":43},"2018-08-01",{"date":598,"type":21},"2027-12-30",{"name":600,"class":74},"University of Nove de Julho",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":608,"targetDuration":4,"studyType":22,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":100},"100617402","phase-2-a-study-of-srsd107-in-participants-with-chronic-coronary-andor-peripheral-arterial-disease-100617402","NCT07318155","A Study of SRSD107 in Participants With Chronic Coronary and\u002For Peripheral Arterial Disease","A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and\u002For Peripheral Arterial Disease","Inclusion Criteria:\n\n* Able to comprehend and willing to sign an ICF and to abide by the study restrictions.\n* Males or females aged 18 to 75 years, inclusive.\n* Body mass index (BMI) between 18.0 and 35.0 kg\u002Fm2, inclusive.\n* History of chronic coronary and\u002For peripheral arterial disease\n\nExclusion Criteria:\n\n* Known bleeding disorder\n* Severe heart failure with known left ventricular ejection fraction \\\u003C35%, or New York Heart Association (NYHA) class III or IV symptoms.\n* Genetic cardiomyopathies or other non-ischemic cardiomyopathies that are not related to atherosclerotic cardiovascular disease.\n* History of ethanol abuse or addictive drug use (cannabis products allowed) within 6 months of screening.\n* Receipt of an investigational drug (IP) within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study.\n* Previous use of SRSD107.",{"count":609,"type":21},104,[481],"The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and\u002For peripheral arterial disease (PAD) with aspirin as background concomitant therapy.",[613,28],"Coronary Artery Disease (CAD)","2026-04-23",{"date":529,"type":43},{"date":617,"type":43},"2025-03-11",{"date":619,"type":21},"2028-12",{"name":621,"class":50},"Sirius Therapeutics Co., Ltd.",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":185,"maxAge":276,"enrollmentInfo":628,"targetDuration":4,"studyType":22,"phases":629,"briefSummary":630,"conditions":631,"keywords":632,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":100},"100635305","evaluation-of-the-effectiveness-of-hybrid-cardiac-rehabilitation-in-peripheral-artery-disease-100635305","NCT07550959","Evaluation of the Effectiveness of Hybrid Cardiac Rehabilitation in Peripheral Artery Disease","Inclusion Criteria:\n\n* Diagnosis of peripheral artery disease with stable intermittent claudication.\n* Fontaine stage I-II or Rutherford category 1-3.\n* Age between 50 and 70 years.\n* Ability to walk independently without assistive devices.\n* Medically stable and eligible for exercise-based rehabilitation.\n* Willingness to participate in the study and to comply with the exercise program.\n* Provision of written informed consent prior to participation.\n\nExclusion Criteria:\n\n* Critical limb ischemia or rest pain.\n* Recent lower extremity revascularization or major surgery within the past 6 months.\n* Unstable cardiovascular conditions (e.g., unstable angina, uncontrolled arrhythmias).\n* Severe pulmonary, neurological, or musculoskeletal disorders limiting exercise participation.\n* Severe cognitive impairment or psychiatric conditions affecting compliance.\n* Participation in another structured exercise or rehabilitation program within the past 3 months.\n* Any medical condition deemed by the investigator to interfere with safe participation in the study.",{"count":479,"type":21},[24],"Peripheral artery disease (PAD) is a common atherosclerotic condition characterized by reduced blood flow to the lower extremities, leading to intermittent claudication, decreased walking capacity, and impaired quality of life. Supervised exercise therapy is recommended as the first-line non-invasive treatment for patients with PAD; however, participation in center-based programs is often limited due to accessibility, time constraints, and symptom-related barriers.\n\nThis randomized controlled study aims to evaluate the clinical effectiveness of a hybrid cardiac rehabilitation program compared with conventional supervised exercise therapy in individuals diagnosed with peripheral artery disease. Participants will be randomly assigned to either a hybrid cardiac rehabilitation group or a supervised exercise therapy group.\n\nThe hybrid cardiac rehabilitation program will combine center-based supervised exercise sessions with home-based telerehabilitation, supported by remote monitoring and wearable activity tracking devices. The supervised exercise therapy group will receive a fully center-based, physiotherapist-supervised exercise program. Both interventions will be delivered over a 12-week period.\n\nPrimary outcomes will include walking performance and functional capacity. Secondary outcomes will assess exercise adherence, symptom severity, physical activity levels, and quality of life. The results of this study are expected to provide evidence on the feasibility and effectiveness of hybrid cardiac rehabilitation as an alternative rehabilitation model for patients with peripheral artery disease.",[28],[633,634,635,636,115],"peripheral arterial disease","Hybrid Cardiac Rehabilitation","Supervised Exercise Therapy","Telerehabilitation","2026-04-22",{"date":639,"type":43},"2026-04-24",{"date":641,"type":21},"2026-09-16",{"date":643,"type":21},"2027-04-16",{"name":645,"class":74},"Biruni University",{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":650,"acronym":4,"eligibilityCriteria":651,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":652,"targetDuration":4,"studyType":22,"phases":653,"briefSummary":654,"conditions":655,"keywords":4,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":661,"leadSponsor":663,"locationsCount":100},"100589700","early-phase-1-study-to-image-inflammatory-activity-of-a-fluorescence-imaging-agent-in-excised-human-artery-plaques-100589700","NCT06957821","Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques","Inclusion Criteria:\n\n* Must have an established diagnosis of severe carotid or peripheral arterial disease (ischemic or aneurysmal) requiring surgery and be sufficiently healthy to undergo surgery\n* Must be age of 18 years or older\n* Must be able to give informed consent\n* Women with childbearing potential must have a negative pregnancy test\n* Estimated glomerular filtration rate ≥ 60 mL\u002Fmin\u002F1.73 m2 (mild renal impairment\n\nExclusion Criteria:\n\n* History of allergic reaction to oral or intravenous contrast agents\n* History of allergic reaction to polyethylene glycol (PEG)\n* History of allergic or anaphylactic reactions\n* Participants who have taken an investigational drug within 14 days of enrollment.\n* Participants with hemodynamic instability\n* Any history of renal failure (estimated Glomerular Filtration Rate (eGFR) \\\u003C60ml\u002Fmin\u002F1.73 m2)\n* Pregnant or lactating females\n* Participants with uncontrolled hypertension defined as persistent systolic blood pressure \\> 180 mm Hg, or diastolic blood pressure \\> 110 mm Hg; those subjects with known HTN should be under these values while under pharmaceutical therapy\n* Severe concurrent illnesses including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, COPD or asthma requiring hospitalization within the past 12 months, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements",{"count":7,"type":21},[190],"Active inflammation plays a key role in causing Coronary Artery Disease (CAD) and Peripheral Arterial Disease (PAD). Since inflammation is so important in how these diseases start, are diagnosed, and treated, being able to see it clearly in each patient could lead to more personalized and effective care - and may help prevent heart attacks. Right now, there's no imaging technology available to clearly see inflammation inside the coronary arteries.\n\nThe investigators hope to learn how an imaging drug; called LUMISIGHT (Pegulicianine) can help detect inflammation in blood vessels compared with saline. If the investigators find out that LUMISIGHT is active in humans, the investigators might be able to use it for detecting plaque risk in the future.",[656,28],"Carotid Artery Diseases","2026-04-15",{"date":659,"type":43},"2026-04-20",{"date":149,"type":21},{"date":662,"type":21},"2029-12",{"name":664,"class":74},"Massachusetts General Hospital"]